FibroBiologics is pursuing a development program for FSdC spheroids with the goal of advancing to clinical trials. The data includes comprehensive preclinical pharmacology and efficacy assessments ...

FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and ...

Phycin has been selected to receive an award through the ReGen Valley Tech Hub Call for Commercialization Resources, marking ...

Sugar overload, chronic stress and modern lifestyles are rewiring your hormones. Together, they spark inflammation, disrupt ...

FibroBiologics is pursuing a development program for CYPS317 with the goal of advancing first-in-human clinical trials following FDA review of the IND filing. The IND submission includes comprehensive ...

FibroBiologics submits IND application with US FDA to initiate clinical trials of CYPS317 in psoriasis patients: Houston Saturday, January 3, 2026, 11:00 Hrs [IST] FibroBiologics ...

How shifting patient expectations and regulatory changes are reshaping Istanbul’s boutique, doctor-led clinics.

Experiments reveal that a time-dependent epistatic interaction influences how mice respond to opioids, and that intracellular fibroblast growth factors also influence opioid sensitivity.

Hong Kong, Shanghai Tuesday, January 6, 2026, 13:00 Hrs [IST] ...

HONG KONG SAR - EQS Newswire - 30 December 2025 - Uni-Bio Science Group Limited ("Uni-Bio Science Group", "Uni-Bio" or "the Group") is pleased to announce the official signing of a tripartite ...

The clinical-stage biotechnology company is seeking regulatory clearance to begin clinical trials of CYPS317, an allogeneic ...

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeuti ...